Abstracts tagged "registry"

Abstract Number: 0604 • ACR Convergence 2023
Is Belimumab Dose Optimization Possible in Patients with Systemic Lupus Erythematosus?: Analysis of This Therapeutic Strategy in a Large Multicenter Cohort of Patients from Spanish Rheumatology Departments
Irene Altabas Gonzalez¹, Jose-Maria Pego-Reigosa², CORAL Mourino Rodriguez³, Norman Jiménez⁴, Andrea Hernández-Martín⁵, Judit Font⁶, Ivette Casafont-Sole⁷, Jose Andres Roman Ivorra⁸, Marta De la Rubia Navarro⁹, Maria Galindo¹⁰, TAREK CARLOS SALMAN MONTE¹¹, Javier Narvaez¹², Paola Vidal-Montal¹³, Maria J. García-Villanueva¹⁴, Sandra Garrote Corral¹⁴, María Ángeles Blázquez Cañamero¹⁵, carlos Marras Fernández-Cid¹⁶, María Piqueras García¹⁷, JULIA MARTINEZ BARRIO¹⁸, Marina Sánchez-Lucas¹⁹, Josefina Cortés Hernández²⁰, Eleonora Penzo²¹, Jaime Calvo Alén²², Juan Ramón de Dios Jiménez de Aberásturi²³, Belén Álvarez Rodríguez²⁴, Margarida Rocha²⁵, Eva Tomero Muriel²⁶, Raúl Menor-Almagro²⁷, Myriam Gandía Martínez²⁸, Jose A Gomez-Puerta²⁹, Beatriz Frade³⁰, Consuelo Ramos-Giráldez³¹, Carmen Trapero Pérez³², MARIA ELVIRA DIEZ ALVAREZ³³, Clara Moriano Morales³³, Alejandro Muñoz³⁴ and Iñigo Rúa-Figueroa³⁵, ¹Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ²Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ³Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ⁴IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ⁵Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain, ⁶Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁸Hospital Universitari i Politècnic la Fe, Valencia, Spain, ⁹Hospital Universitario y Politécnico de la Fe, Valencia, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹²Hospital Universitario de Bellvitge, Barcelona, Spain, ¹³Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁴Hospital Ramón y Cajal, Madrid, Spain, ¹⁵Rheumatology Department Hospital Ramon y Cajal, Madrid, Spain, ¹⁶Rheumatology, Hospital Virgen Arrixaca, Murcia, Spain, ¹⁷Hospital Virgen de la Arrixaca de Murcia, Murcia, Spain, ¹⁸Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ¹⁹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²⁰Lupus Unit, Rheumatology Department, Vall d’Hebron Hospitals, Barcelona, Spain, ²¹Hospital Universitario Valle d´ Hebrón, Barcelona, Spain, ²²Hospital Universitario Araba, Vitoria, Spain, ²³Hospital Universitario Araba, Álava, Spain, ²⁴Hospital de Araba, Vitoria, Spain, ²⁵Osakidetza, Bilbo, Spain, ²⁶Rheumatology, Hospital La Princesa, Madrid, Spain, ²⁷Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ²⁸Hospital de Jerez, Jerez, Spain, ²⁹Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain, ³⁰Hospital Clinic, Barcelona, Spain, ³¹Rheumatology Department Hospital Universitario Virgen de Valme, Sevilla, Spain, ³²Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain, ³³Rheumatology, Hospital Universitario de León, León, Spain, ³⁴Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ³⁵Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain
Background/Purpose: Belimumab (BLM) is an IgG-1l anti-BAFF monoclonal antibody effective in patients with systemic lupus erythematosus (SLE), being used increasingly. However, there are no published…
Abstract Number: 1412 • ACR Convergence 2023
Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J. Mease¹, Alexis R Ogdie², John Tesser³, Natalie shiff⁴, Iris Lin⁵, Soumya Chakravarty⁶, Mike Kelleman⁷, Rhiannon Dodge⁷, Robert McLean⁷, Aaron Broadwell⁸, Arthur Kavanaugh⁹ and Joseph F. Merola¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁴Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁵Janssen, Horsham, PA, ⁶Immunology, Janssen Scientific Affairs, LLC / Division of Rheumatology, Drexel University College of Medicine, Villanova, PA, ⁷CorEvitas, LLC, Waltham, MA, ⁸Department of Rheumatology, Rheumatology and Osteoporosis Specialists, Shreveport, LA, ⁹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ¹⁰Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Guselkumab (GUS) has demonstrated significant efficacy across disease domains in controlled clinical trials of patients (pts) with active PsA.1,2 Recent CorEvitas PsA/SpA Registry analyses…
Abstract Number: 2394 • ACR Convergence 2023
18f-FDG-PET/CT for Giant Cell Arteritis Detection of Large Vessel Vasculitis: What Should We Take into Consideration? Analytical Study of the Arteser Registry
Paula V. Estrada-Alarcón¹, Marta Domínguez², Rafael Benito Melero-Gonzalez³, Eugenio De Miguel⁴, Maria. T Silva-Diaz⁵, Jesús Alejandro Valero⁶, Ismael González⁷, Julio Sanchez Martin⁸, Javier Narvaez⁹, Eva Galindez-Agirregoikoa¹⁰, javier Mendizábal¹¹, lydia Abasolo¹², Javier Loricera⁸, Alejandro Muñoz¹³, Santos Castañeda¹⁴, Patricia Moya¹⁵, patricia Moran Alvarez¹⁶, Vanesa Navarro¹⁷, Carles Galisteo¹⁸, Ivette Casafont-Solé¹⁹, Jose Andres Roman Ivorra²⁰, TAREK CARLOS SALMAN MONTE²¹, Margarida Rocha²², Carlota Laura Iñiguez²³, Alicia García²⁴, Cristina Campos²⁵, María Alcalde²⁶, Antonio Juan Mas²⁷, Francisco Javier Prado²⁸, Ricardo Blanco²⁹ and On Behalf of ARTESER Working Group³⁰, ¹Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Vigo, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Department of Rheumatology, Hospital Universitario Donostia, San Sebastián, Spain, ⁷Hospital Universitario de León, León, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Basurto University Hospital, Bilbao, Spain, ¹¹Complejo Hospitalario de Navarra, Pamplona, Spain, ¹²Hospital Clínico San Carlos, Madrid, Spain, ¹³Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁶Hospital Ramón y Cajal, Madrid, Spain, ¹⁷H Moisès Broggi, Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitario Parc Taulí, Sabadell, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitari i Politècnic la Fe, Valencia, Spain, ²¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²²Osakidetza, Bilbo, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Hospital Universitario de Canarias, Islas Canarias, ²⁵Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ²⁶Hospital Severo Ochoa, Madrid, Spain, ²⁷Hospital Universitario Son Llàtzer, Mallorca, Spain, ²⁸Research department Hospital Infantil de México Federico Gómez, Mexico City, Mexico, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁰SER, Spain
Background/Purpose: Imaging studies in patients with giant cell arteritis (GCA) and suspected large vessel vasculitis (LVV) are sensitive, increasingly available, and less aggressive than temporal…
Abstract Number: 0831 • ACR Convergence 2023
Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study
Sarah Ringold¹, George Tomlinson², Laura Schanberg³, vincent del gaizo⁴, Katherine Murphy⁵, Brian Feldman⁶, Mei-Sing Ong⁷, Marc Natter⁸, Yukiko Kimura⁹ and For The CARRA Registry Investgators⁴, ¹Seattle Children's Hospital, Seattle, WA, ²University of Toronto, Toronto, ON, Canada, ³Duke University School of Medicine, Durham, NC, ⁴CARRA, Inc, Washington, DC, ⁵Non-clinical, New Orleans, LA, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ⁸Harvard Medical School, Boston, MA, ⁹Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: The STOP-JIA study was designed to compare the effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Consensus Treatment Plans (CTPs) for untreated…
Abstract Number: 1439 • ACR Convergence 2023
Better Drug Retention on anti-IL17A Compared to Anti-TNF Therapy Despite Its Inferior Effect on Composite Joint Indexes and Quality of Life in Patients with PsA–analysis from the Czech Biologics Registry ATTRA
Jakub Zavada¹, Jana Baranová², Karel Pavelka³, Jiri Vencovsky⁴, Pavel Horak⁵, Lenka Klementová⁶ and Ladislav Senolt⁷, ¹Institute of Rheumatology; Charles University, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Brno, Czech Republic, ³Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Department of Internal Medicine III- Nephrology, Rheumatology, Endocrinology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic, ⁶Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: To compare drug survival, effectiveness and safety of anti-IL17A with anti-TNF drugs as first line biologic therapy in patients (pts) with PsA using real…
Abstract Number: 2556 • ACR Convergence 2023
End-of-Life in Systemic Lupus Erythematosus Beset by Increased Flares and Higher Treatment Burden: Data from a Prospective Large Multinational Cohort
Jiacai Cho¹, Liang Shen², Rangi Kandane-Rathnayake³, Vera Golder³, Worawit Louthrenoo⁴, Yi-Hsing Chen⁵, Laniyati Hamijoyo⁶, Shue-Fen Luo⁷, Yeong-Jian J Wu⁸, Leonid Zamora⁹, Zhanguo Li¹⁰, Sargunan Sockalingam¹¹, Yasuhiro Katsumata¹², Masayoshi Harigai¹², Yanjie Hao¹³, Zhuoli Zhang¹⁴, BMDB Basnayake¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Sang-Cheol Bae¹⁹, Shereen Oon²⁰, Sean O’Neill²¹, Fiona Goldblatt²², Kristine Ng²³, Annie Law²⁴, Nicola Tugnet²⁵, Sunil Kumar²⁶, Cherica Tee²⁷, Michael Tee²⁷, Naoaki Ohkubo²⁸, Yoshiya Tanaka²⁸, Sandra Navarra⁹, Chak Sing Lau²⁹, Alberta Hoi³⁰, Mandana Nikpour³¹, Eric Morand³² and Aisha Lateef³³, ¹National University Hospital, Singapore, Singapore, ²National University of Singapore, Singapore, Singapore, ³Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁴Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Taichung Veterans General Hospital, Taichung, Taiwan, ⁶Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, ⁷Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, ⁹University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹⁰Peking University People’s Hospital, Beijing, China, ¹¹University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, ¹²Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹³The University of Melbourne Department of Medicine at St Vincents Hospital Melbourne, Melbourne, Australia, ¹⁴Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁵Division of Nephrology, Teaching Hospital Kandy, Adelaide, Australia, ¹⁶Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, ¹⁷Keio University, Keio, Japan, ¹⁸Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ¹⁹Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ²⁰Department of Medicine, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ²¹Department of Medicine, University of New South Wales, Kensington, Australia, ²²Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ²³Waitemata DHB, Auckland, New Zealand, ²⁴Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²⁵Auckland District Health Board, Auckland, New Zealand, ²⁶Middlemore Hospital, Auckland, New Zealand, ²⁷University of the Philippines, Manila, Philippines, ²⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁹University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³⁰Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ³¹The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ³²Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³³National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore
Background/Purpose: SLE patients suffer high symptom burden at the end-of-life. However, the course of disease and treatment burden in the last year of life have…
Abstract Number: 0980 • ACR Convergence 2023
Temporal Trends in Incidence Rates of Seropositive and Seronegative Rheumatoid Arthritis: A Danish Nationwide Population-based Study
Bolette Soussi¹, René Cordtz², Kirsten Duch², Salome Kristensen³, Asta Linauskas⁴, Christian Bork⁵, Erik Schmidt⁶ and Lene Dreyer³, ¹Center of Rheumatic Research Aalborg, Department of Rheumatology, and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark, ²Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ³Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁴Department of Rheumatology, North Denmark Region Hospital, and Department of Clinical Medicine, Aalborg University, Hjørring, Denmark, ⁵Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark, ⁶Department of Medicine and Cardiology, Viborg Regional Hospital, and Department of Clinical Medicine, Aalborg University, Viborg, Aalborg, Denmark
Background/Purpose: With growing availability of autoantibody testing and autoantibodies gaining more weight in the 2010 ACR/EULAR classification criteria of rheumatoid arthritis (RA), an increasing incidence…
Abstract Number: 1629 • ACR Convergence 2023
Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative
Kaleb Michaud¹, Sofia Pedro², Shreena Kamlesh Gandhi³ and Frederick Wolfe², ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Kansas University School of Medicine, Wichita, KS
Background/Purpose: Long COVID, also known as Post COVID syndrome or postacute sequelae of SARS-CoV-2 infection, refers to the development of persistent or new symptoms lasting…
Abstract Number: 0987 • ACR Convergence 2023
Risk Factors and Predictors of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
Vijaya Rivera Terán¹, David Vega Morales², Miguel Angel Saavedra Salinas³, Iris Colunga⁴, Sandra Carrillo Vazquez⁵, Dafhne Miranda Hernández⁶, Sergio Durán Barragán⁷, Erick Adrián Zamora Tehozol⁸, Daniel Xavier Xibillé Friedman⁹, Angel Alejandro Castillo Ortiz¹⁰, Sandra Sicsik Ayala¹¹, Fedra Irazoque Palazuelos⁵, Julio César Casasola Vargas¹², Angelica Peña¹³, Omar Eloy Muñoz Monroy¹⁴, Azucena Ramos Sánchez², Luis Valdés Corona¹⁵, Javier Merayo-Chalico¹⁶, Estefania Torres Valdez¹³, Aleni Paz Viscarra¹⁵, Samara Mendieta Zerón¹⁷ and Deshiré Alpízar Rodríguez¹, ¹Colegio Mexicano de Reumatología, Mexico City, Mexico, ²Instituto Mexicano del Seguro Social, Monterrey, Mexico, ³IMSS, Mexico City, Mexico, ⁴Hospital Universitario UANL, Monterrey, Mexico, ⁵Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico, ⁶Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁷Consulta Privada, Guadalajara, Mexico, ⁸Centro Médico Pensiones, Mérida, Mexico, ⁹Práctica Privada, Cuernavaca, Mexico, ¹⁰Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mérida, Mexico, ¹¹Instituto Mexicano del Seguro Social, Torreón, Mexico, ¹²Instituto de Seguridad Social del Estado de México y Municipios, Mexico City, Mexico, ¹³Instituto Mexicano del Seguro Social, Querétaro, Mexico, ¹⁴Hospital Central Militar, Mexico City, Mexico, ¹⁵Práctica Privada, Mexico City, Mexico, ¹⁶Reumátika, Centro de Vanguardia en Reumatología de la Ciudad de México, Mexico City, Mexico, ¹⁷Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico
Background/Purpose: Genetic, demographic, clinical, and immunological factors have been related with the response to treatment in inflammatory rheumatic diseases, such as rheumatoid arthritis (RA) and…
Abstract Number: 1632 • ACR Convergence 2023
Incident Malignancies in Patients with Rheumatoid Arthritis in Daily Rheumatological Care
Martin Schaefer¹, Yvette Meissner¹, Bernhard Manger², Sylvia Berger³, Karin Rockwitz⁴, Anne Regierer⁵ and Anja Strangfeld¹, ¹German Rheumatism Research Center, Berlin, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Rheumatologist, Naunhof, Germany, ⁴Rheumatologist, Goslar, Germany, ⁵Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: In 2021, the European and US-American regulatory agencies EMA and FDA issued warnings about malignancy risk associated with the Janus kinase inhibitor (JAKi) tofacitinib…
Abstract Number: 0988 • ACR Convergence 2023
Elderly Patients’ Discontinuation of Biologic DMARDs in Patients with Rheumatic Diseases: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
Vijaya Rivera Terán¹, David Vega Morales², Miguel Angel Saavedra Salinas³, Daniel Xavier Xibillé Friedman⁴, Iris Colunga⁵, Sandra Carrillo Vazquez⁶, Dafhne Miranda Hernández⁷, Sergio Durán Barragán⁸, Erick Adrián Zamora Tehozol⁹, Angel Alejandro Castillo Ortiz¹⁰, Sandra Sicsik Ayala¹¹, Fedra Irazoque Palazuelos⁶, Julio César Casasola Vargas¹², Angelica Peña¹³, Omar Eloy Muñoz Monroy¹⁴, Azucena Ramos Sánchez², Luis Valdés Corona¹⁵, Javier Merayo-Chalico¹⁶, Estefania Torres Valdez¹³, Aleni Paz Viscarra¹⁵ and Deshiré Alpízar Rodríguez¹, ¹Colegio Mexicano de Reumatología, Mexico City, Mexico, ²Instituto Mexicano del Seguro Social, Monterrey, Mexico, ³IMSS, Mexico City, Mexico, ⁴Práctica Privada, Cuernavaca, Mexico, ⁵Hospital Universitario UANL, Monterrey, Mexico, ⁶Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico, ⁷Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁸Consulta Privada, Guadalajara, Mexico, ⁹Centro Médico Pensiones, Mérida, Mexico, ¹⁰Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mérida, Mexico, ¹¹Instituto Mexicano del Seguro Social, Torreón, Mexico, ¹²Instituto de Seguridad Social del Estado de México y Municipios, Mexico City, Mexico, ¹³Instituto Mexicano del Seguro Social, Querétaro, Mexico, ¹⁴Hospital Central Militar, Mexico City, Mexico, ¹⁵Práctica Privada, Mexico City, Mexico, ¹⁶Reumátika, Centro de Vanguardia en Reumatología de la Ciudad de México, Mexico City, Mexico
Background/Purpose: The approach to elderly patients (≥60 years) with rheumatic diseases offers certain difficulties and uncertainties. Older adults are a particularly vulnerable group who often…
Abstract Number: 1692 • ACR Convergence 2023
Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study)
Romain Aymon¹, Denis Mongin², Burkhard Leeb³, Monika Mustak-Blagusz⁴, Jakub Závada⁵, Karel Pavelka⁶, Dan Nordstrom⁷, Nina Trokovic⁸, Florenzo Iannone⁹, Catalin Codreanu¹⁰, Ziga Rotar¹¹, Tore Kvien¹², Sella Provan¹³, Manuel Enrique Pombo Suarez¹⁴, Fernando Alonso¹⁵, Fatos Onen¹⁶, Nevsun Inanc¹⁷, Louis Coupal¹⁸, Denis Choquette¹⁹, Galina Lukina²⁰, Ori Elkayam²¹, Victoria Furer²¹, Ana Maria Rodrigues²², Delphine COURVOISIER²³, Axel Finckh²⁴, Michael Nissen² and Kim Lauper²⁵, ¹Geneva University Hospitals, Collonges-sous-Salève, France, ²Geneva University Hospitals, Geneva, Switzerland, ³BioReg, Stockerau, Austria, ⁴BioReg, Vienna, Austria, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁷Helsinki University Hospital, Helsinki, Finland, ⁸University of Helsinki, Helsinki, Finland, ⁹Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁰Center for Rheumatic Diseases, Bucharest, Romania, ¹¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹²Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹³Diakonhjemmet Hospital, Oslo, Norway, ¹⁴Hospital Clínico Universitario, Santiago de Compostela, Spain, ¹⁵Spanish Society of Rheumatology, Madrid, Spain, ¹⁶Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁷Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, ¹⁸Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁹Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ²⁰Federal state budgetary scientific institution "V.A. Nasonova Research Institute of Rheumatology", Moscow, Russia, ²¹Tel Aviv Medical Center, Tel Aviv, Israel, ²²Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ²³Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²⁴HUG, Geneva, Switzerland, ²⁵Geneva University Hospitals, Genève, Switzerland
Background/Purpose: JAK-inhibitors (JAKi) are increasingly being prescribed to treat various inflammatory conditions, including psoriatic arthritis (PsA). While the understanding of JAKi efficacy and safety in…
Abstract Number: 0139 • ACR Convergence 2023
Systemic Vasculitides in Portugal and Brazil: Preliminary Results from the Reuma.pt/vasculitis Registry
Mariana de Aguiar¹, Alexandre wagner Silva de Souza², Joana Martinho³, Adriana Carones⁴, Ana Beatriz Bacchiega de Freitas⁵, Ana Catarina Duarte⁶, Ana Filipa Águeda⁷, Camila Souto Oliveira Elias⁸, Catarina Cortesão⁹, Catarina Soares¹⁰, Carla Macieira¹¹, Carlos Eduardo Garcez Teixeira¹², Daniela Peixoto¹³, Duarte Vinha³, Estela Nogueira³, Fabricia Simil¹⁴, Francisca Guimarães¹³, Frederico Rajão Martins¹⁵, Gilda Ferreira¹⁶, Helena Assunção⁴, Heloisa Rulff⁸, Jorge Pestana Lopes⁶, José Costa³, Julia Medeiros¹⁷, Lilian Santos Porto¹⁸, Luiz Felipe Adsuara¹⁷, Manuella Ochtrop⁸, Maria João Gonçalves¹⁹, Mariana Diz Lopes²⁰, Matheus Vieira²¹, Nikita Khmelinskii¹¹, Rita Torres²², Sarah Neaime¹, Vitor Teixeira²³, Zoraida Sachetto¹² and Cristina Ponte²⁴, ¹Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²Division of Rheumatology, Medical School, Universidade Federal de São Paulo, São Paulo, Brazil, ³Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, ⁴Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁵Faculdade de Ciências da Saúde de Barretos, Barretos, Brazil, ⁶Hospital Garcia de Orta, Almada, Portugal, ⁷Centro Hospitalar Universitário Cova da Beira, Covilhã, Portugal, ⁸Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹Instituto Português de Reumatologia, Lisboa, Portugal, ¹⁰Centro Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal, ¹¹Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ¹²Universidade Estadual de Campinas, Campinas, Brazil, ¹³Centro Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ¹⁴Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ¹⁵Department of Rheumatology, University Hospital Centre of Algarve, Faro, Portugal, ¹⁶Federal University of Minas Gerais, Belo Horizonte, Brazil, ¹⁷Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ¹⁸Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Brazil, ¹⁹Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal, ²⁰Centro Hospitalar Universitário de São João, Porto, Portugal, ²¹Universidade Federal de São Paulo; Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ²²Hospital Egas Moniz, Lisboa, Portugal, ²³Hospital de Faro, CHUA, Lisbon, Portugal, ²⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
Background/Purpose: The epidemiology of vasculitis varies widely across different geographic areas of the world which may be due to different ethnic and environmental factors. Brazil…
Abstract Number: 1024 • ACR Convergence 2023
Relationship Between Race and Ethnicity, Time to Diagnosis, and Disease Activity for Children with Juvenile Idiopathic Arthritis in the CARRA Registry
Sarah McGuire¹, Tania Atanassova², Joanna Madej², Manuel Jimenez², Daniel Horton¹ and for the CARRA TMJ Arthritis Workgroup³, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers, Robert Wood Johnson Medical School, New Brunswick, NJ, ³Childhood Arthritis and Rheumatology Research Alliance, Washington, DC
Background/Purpose: Compared to non-Hispanic White children, Black children diagnosed with juvenile idiopathic arthritis (JIA) have more severe disease at diagnosis and worse outcomes, such as…
Abstract Number: 1850 • ACR Convergence 2023
Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data
Andriko Palmowski¹, Eric Roberts², Jing Li², Emma Kersey², Rachael Stovall², Frank Buttgereit³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of California San Francisco, San Francisco, CA, ³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ⁴University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁵UCSF / SFVA, San Francisco, CA
Background/Purpose: According to recent ACR and EULAR rheumatoid arthritis (RA) guidelines, glucocorticoids (GCs) should only be used for brief periods or not at all. Our…

« Previous Page
1
…
3
4
5
6
7
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].